TREM2 is associated with tumor immunity and implies poor prognosis in glioma

被引:16
作者
Yu, Mingchen [1 ]
Chang, Yuanhao [1 ]
Zhai, You [1 ]
Pang, Bo [1 ]
Wang, Peng [2 ]
Li, Guanzhang [1 ,2 ]
Jiang, Tao [1 ,2 ,3 ,4 ,5 ,6 ]
Zeng, Fan [1 ,4 ,5 ]
机构
[1] Capital Med Univ, Beijing Neurosurg Inst, Dept Mol Neuropathol, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China
[3] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
[4] Chinese Glioma Genome Atlas Network CGGA, Beijing, Peoples R China
[5] Asian Glioma Genome Atlas Network AGGA, Beijing, Peoples R China
[6] Chinese Acad Med Sci, Res Unit Accurate Diag Treatment & Translat Med Br, Beijing, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 13卷
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
glioma; TREM2; macrophage; prognosis; tumor immunity; MACROPHAGES; ACTIVATION; LANDSCAPE; MICROGLIA; REVEAL;
D O I
10.3389/fimmu.2022.1089266
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Triggering receptor expressed on myeloid cells 2 (TREM2) is expressed in myeloid cells of the central nervous system (CNS), which mediate the immunological response in a variety of diseases. Uncertain is the function of TREM2 in glioma and tumor immune responses. In this research, the expression patterns of TREM2 in glioma were analyzed, along with its prognostic value and functional roles. TREM2 expression is increased in glioblastomas, gliomas with a mesenchymal subtype, gliomas with wild-type isocitrate dehydrogenase, and gliomas without 1p/19q deletion, all of which suggest the aggressiveness and poor prognosis of gliomas. Gene ontology, KEGG, and Gene set variation analyses indicated that TREM2 may serve as an immune response mediator. However, the function of T cells against tumor cells was negatively correlated with TREM2, suggesting that TREM2 may suppress tumor immunity. Further investigation demonstrated a correlation between TREM2 expression and immune checkpoint expression. CIBERSORT research revealed a link between a higher TREM2 expression level and the enrichment of tumor-associated macrophages, especially M2 subtype. Single-cell analysis and multiple immunohistochemical staining results showed that microglia and macrophage cells expressed TREM2. Immunofluorescent staining indicated that knocking down the expression of TREM2 would result in a decrease in M2 polarization. TREM2 was discovered to be an independent prognostic factor in glioma. In conclusion, our findings revealed that TREM2 was significantly expressed in microglia and macrophage cells and was intimately associated with the tumor immune microenvironment. Thus, it is expected that small-molecule medications targeting TREM2 or monoclonal antibodies would enhance the efficacy of glioma immunotherapy.
引用
收藏
页数:15
相关论文
共 44 条
  • [31] Exciting New Advances in Neuro-Oncology The Avenue to a Cure for Malignant Glioma
    Van Meir, Erwin G.
    Hadjipanayis, Costas G.
    Norden, Andrew D.
    Shu, Hui-Kuo
    Wen, Patrick Y.
    Olson, Jeffrey J.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2010, 60 (03) : 166 - 193
  • [32] Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
    Verhaak, Roel G. W.
    Hoadley, Katherine A.
    Purdom, Elizabeth
    Wang, Victoria
    Qi, Yuan
    Wilkerson, Matthew D.
    Miller, C. Ryan
    Ding, Li
    Golub, Todd
    Mesirov, Jill P.
    Alexe, Gabriele
    Lawrence, Michael
    O'Kelly, Michael
    Tamayo, Pablo
    Weir, Barbara A.
    Gabriel, Stacey
    Winckler, Wendy
    Gupta, Supriya
    Jakkula, Lakshmi
    Feiler, Heidi S.
    Hodgson, J. Graeme
    James, C. David
    Sarkaria, Jann N.
    Brennan, Cameron
    Kahn, Ari
    Spellman, Paul T.
    Wilson, Richard K.
    Speed, Terence P.
    Gray, Joe W.
    Meyerson, Matthew
    Getz, Gad
    Perou, Charles M.
    Hayes, D. Neil
    [J]. CANCER CELL, 2010, 17 (01) : 98 - 110
  • [33] Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity
    von Roemeling, Christina A.
    Wang, Yifan
    Qie, Yaqing
    Yuan, Hengfeng
    Zhao, Hai
    Liu, Xiujie
    Yang, Zhaogang
    Yang, Mingming
    Deng, Weiye
    Bruno, Katelyn A.
    Chan, Charles K.
    Lee, Andrew S.
    Rosenfeld, Stephen S.
    Yun, Kyuson
    Johnson, Aaron J.
    Mitchell, Duane A.
    Jiang, Wen
    Kim, Betty Y. S.
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [34] The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
    Wang, Hao-Yuan
    Tang, Kai
    Liang, Ting-Yu
    Zhang, Wei-Zhong
    Li, Ji-Ye
    Wang, Wen
    Hu, Hui-Min
    Li, Ming-Yang
    Wang, Hui-Qing
    He, Xiao-Zheng
    Zhu, Zhi-Yuan
    Liu, Yan-Wei
    Zhang, Shi-Zhong
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [35] Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications
    Wei, Jun
    Chen, Peiwen
    Gupta, Pravesh
    Ott, Martina
    Zamler, Daniel
    Kassab, Cynthia
    Bhat, Krishna P.
    Curran, Michael A.
    de Groot, John F.
    Heimberger, Amy B.
    [J]. NEURO-ONCOLOGY, 2020, 22 (02) : 180 - 194
  • [36] Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
    Wen, Patrick Y.
    Weller, Michael
    Lee, Eudocia Quant
    Alexander, Brian M.
    Barnholtz-Sloan, Jill S.
    Barthel, Floris P.
    Batchelor, Tracy T.
    Bindra, Ranjit S.
    Chang, Susan M.
    Chiocca, E. Antonio
    Cloughesy, Timothy F.
    DeGroot, John F.
    Galanis, Evanthia
    Gilbert, Mark R.
    Hegi, Monika E.
    Horbinski, Craig
    Huang, Raymond Y.
    Lassman, Andrew B.
    Le Rhun, Emilie
    Lim, Michael
    Mehta, Minesh P.
    Mellinghoff, Ingo K.
    Minniti, Giuseppe
    Nathanson, David
    Platten, Michael
    Preusser, Matthias
    Roth, Patrick
    Sanson, Marc
    Schiff, David
    Short, Susan C.
    Taphoorn, Martin J. B.
    Tonn, Joerg-Christian
    Tsang, Jonathan
    Verhaak, Roel G. W.
    von Deimling, Andreas
    Wick, Wolfgang
    Zadeh, Gelareh
    Reardon, David A.
    Aldape, Kenneth D.
    van den Bent, Martin J.
    [J]. NEURO-ONCOLOGY, 2020, 22 (08) : 1073 - 1113
  • [37] Lomustine and Bevacizumab in Progressive Glioblastoma
    Wick, Wolfgang
    Gorlia, Thierry
    Bendszus, Martin
    Taphoorn, Martin
    Sahm, Felix
    Harting, Inga
    Brandes, Alba A.
    Taal, Walter
    Domont, Julien
    Idbaih, Ahmed
    Campone, Mario
    Clement, Paul M.
    Stupp, Roger
    Fabbro, Michel
    Le Rhun, Emilie
    Dubois, Francois
    Weller, Michael
    von Deimling, Andreas
    Golfinopoulos, Vassilis
    Bromberg, Jacoline C.
    Platten, Michael
    Klein, Martin
    van den Bent, Martin J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1954 - 1963
  • [38] TREM-2 promotes Th1 responses by interacting with the CD3ζ-ZAP70 complex following Mycobacterium tuberculosis infection
    Wu, Yongjian
    Wu, Minhao
    Ming, Siqi
    Zhan, Xiaoxia
    Hu, Shengfeng
    Li, Xingyu
    Yin, Huan
    Cao, Can
    Liu, Jiao
    Li, Jinai
    Wu, Zhilong
    Zhou, Jie
    Liu, Lei
    Gong, Sitang
    He, Duanman
    Huang, Xi
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (17)
  • [39] TREM2, Microglia, and Neurodegenerative Diseases
    Yeh, Felix L.
    Hansen, David V.
    Sheng, Morgan
    [J]. TRENDS IN MOLECULAR MEDICINE, 2017, 23 (06) : 512 - 533
  • [40] Zhai Y, 2019, AM J CANCER RES, V9, P2554